Methods | Country: USA Setting/Design: Multicentre Time frame: NS Randomisation method: NS Blinding ‐ Participants: Yes ‐ Investigators: Yes ‐ Outcome assessors: Yes ‐ Data analysis: No Intention‐to‐treat: Yes Follow‐up period: mean 3.4 years Loss to follow‐up: 3 | |
Participants |
Inclusion criteria
Losartan group
Placebo group
Exclusion criteria
|
|
Interventions |
Losartan group
50‐100 mg/d Placebo group Co‐interventions CCB, diuretics, alpha‐blockers, beta‐blockers and centrally acting agents |
|
Outcomes |
|
|
Notes | ||
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Allocation concealment? | Unclear risk | B ‐ Unclear |